Freshfields advises Bioeq IP on the out-licensing of its Lucentis biosimilar to Coherus Bioscience
Freshfields Bruckhaus Deringer LLP (‘Freshfields‘) has advised Bioeq IP AG (‘Bioeq’), a biopharmaceutical joint venture between the Polpharma Biologics Group and the Strüngmann Group, on its license and development agreement with Coherus BioSciences, Inc. (‘Coherus’).
The agreement enables Coherus to exclusively market and distribute Bioeq’s biosimilar candidate to Lucentis® (ranibizumab) in the United States. The launch of the product is planned in 2021.
According to the license and development agreement, Bioeq will receive upfront and launch milestone payments and the parties will share the profits achieved with sales of the product in the U.S.
Bioeq is a Swiss biopharmaceutical company active in the development, licensing and commercialization of biosimilars. Coherus is a leading biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets.
The Freshfields team comprised partner Jochen Dieselhorst and associate Philipp Lehmann.
Notes for Editors
About Freshfields Bruckhaus Deringer LLP
Freshfields Bruckhaus Deringer LLP is a global law firm with a long-standing track record of successfully supporting the world's leading national and multinational corporations, financial institutions and governments on ground-breaking and business-critical mandates. Our 2,800 plus lawyers deliver results worldwide through our own offices and alongside leading local firms. Our commitment, local and multi-national expertise and business know-how means our clients rely on us when it matters most.